Analysts Issue Forecasts for COGT Q1 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Cogent Biosciences in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the technology company will post earnings of ($0.57) per share for the quarter. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences’ Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.55) EPS and FY2027 earnings at $0.72 EPS.

Cogent Biosciences (NASDAQ:COGT) last released its earnings results on Tuesday, November 12th. The technology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). During the same quarter in the previous year, the company earned ($0.64) earnings per share.

Several other equities analysts also recently weighed in on the company. Wedbush reissued a “neutral” rating and set a $11.00 target price on shares of Cogent Biosciences in a research report on Monday, January 13th. HC Wainwright cut their price objective on Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. JPMorgan Chase & Co. upped their price objective on Cogent Biosciences from $19.00 to $21.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Finally, Needham & Company LLC downgraded Cogent Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.33.

Cogent Biosciences Stock Performance

NASDAQ COGT opened at $8.74 on Friday. The company has a market cap of $965.42 million, a P/E ratio of -3.52 and a beta of 1.77. The business’s 50 day moving average price is $8.42 and its 200-day moving average price is $9.67. Cogent Biosciences has a fifty-two week low of $5.37 and a fifty-two week high of $12.61.

Institutional Investors Weigh In On Cogent Biosciences

Several hedge funds have recently made changes to their positions in COGT. Values First Advisors Inc. purchased a new stake in shares of Cogent Biosciences in the 3rd quarter worth $32,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Cogent Biosciences by 38.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,959 shares of the technology company’s stock worth $43,000 after buying an additional 1,104 shares during the period. nVerses Capital LLC purchased a new stake in shares of Cogent Biosciences in the 3rd quarter worth $76,000. E Fund Management Co. Ltd. purchased a new stake in shares of Cogent Biosciences in the 4th quarter worth $89,000. Finally, Proficio Capital Partners LLC purchased a new stake in shares of Cogent Biosciences in the 4th quarter worth $93,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.